Cervix Cancer, Vaginal Cancer
Conditions
Keywords
Cervix Cancer, Vaginal Cancer, Sexual function, Brachytherapy, Radiotherapy
Brief summary
Prospective, monocentric study evaluating the impact of a nurse-led sexological follow-up on sexual function in patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy. The study procedure will consist of nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy. Evolution of female sexual function and vaginal symptoms will be done through clinical examinations and completion of quality of life and female sexual function questionnaires during radiation oncologist consultation and/or nurse-led sexological consultations until one year after end of brachytherapy. Study participation of each patient will be 12 months.
Interventions
OTHERPatients with cervix or vaginal cancer treated by radiotherapy and brachytherapy
* Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy. * Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24.
Sponsors
Institut Claudius Regaud
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 18 years or older 2. Woman diagnosed with cervix or vaginal cancer, for whom a treatment by radiotherapy and brachytherapy has been decided 3. Patient receiving for the first time an utero-vaginal or vaginal brachytherapy at Institut Universitaire du Cancer de Toulouse - Oncopole 4. Easter Cooperative Oncology Group (ECOG) Performance Status ≤ 2 5. All patients are eligible, regardless of their relationship status (in couple or not), their sexual orientation, and their hormonal status 6. Patient willing to give informed consent before the study and before performing any study-related procedures 7. Patient affiliated to a Social Health Insurance in France
Exclusion criteria
1. Patient not understanding the French language 2. Patient for whom surgical treatment and brachytherapy has been decided 3. Any psychological, familial, sociological or geographical condition that potentially hampers compliance with the study protocol and follow-up after treatment discontinuation schedule 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Female Sexual Function Index score (evolution between inclusion and 1 year after brachytherapy) assessed using FSFI (Female Sexual Function Index) Questionnaire | 12 months for each patient |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life assessed using QLQ-C30 questionnaire (Quality of Life Questionnaire-Core 30) | 12 months for each patient |
| Quality of life specific for cervix cancer assessed using QLQ-CX24 questionnaire (Quality-of-Life questionnaire cervical cancer module) | 12 months for each patient |
| Vaginal symptoms assessed using NCI-CTCAE version 5 (National Cancer Institute Common Toxicity Criteria for Adverse Events) | 12 months for each patient |
Countries
France
Outcome results
None listed